E. Quirk

发表

HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.

D. Mehrotra, R. Mogg, M. Lally, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Speaker Abstracts

K. White, D. Ward, P. Sax, 2017, Journal of the International AIDS Society.

HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico

M. Lederman, D. Podzamczer, D. Kuritzkes, 2015, Journal of the International AIDS Society.

Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

J. Kublin, D. Mehrotra, J. Shiver, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants

R. K. Evans, D. Mehrotra, R. Leavitt, 2014, Open forum infectious diseases.

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

D. Mehrotra, J. Shiver, R. Leavitt, 2009, Clinical and Vaccine Immunology.

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

K. White, Ross Martin, D. SenGupta, 2019, Antimicrobial Agents and Chemotherapy.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver‐Distributed Farnesoid X‐Receptor Agonist TERN‐101 in Healthy Volunteers

Christopher Jones, M. Fenaux, M. Charlton, 2021, Clinical pharmacology in drug development.

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

K. White, J. Gallant, A. Cheng, 2017, Journal of acquired immune deficiency syndromes.

Osteoporosis in HIV-infected patients

W. Powderly, R. Groger, E. Quirk, 2004 .

1056 MK-7009 SIGNIFICANTLY IMPROVES RAPID VIRAL RESPONSE (RVR) IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION

M. Manns, C. Yeh, E. Gane, 2009 .

Bioequivalence of the Rilpivirine/Emtricitabine/Tenofovir AlafenamideSingle-Tablet Regimen

B. Kearney, H. Cao, E. Quirk, 2016 .

Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy.

K. Yarasheski, D. Reeds, S. Klein, 2005, Metabolism: clinical and experimental.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

K. White, P. Sax, A. Zolopa, 2012, The Lancet.

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

D. Podzamczer, K. White, J. Gallant, 2017, The Lancet.

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.

K. White, D. Ward, P. Sax, 2017, The lancet. HIV.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

K. White, H. Stellbrink, P. Sax, 2017, The Lancet.

P176 Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir

B. Kearney, Xuelian Wei, E. Quirk, 2017 .

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.

S. Hammer, J. Kublin, S. Self, 2010, AIDS research and human retroviruses.

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.

J. Kublin, C. del Rio, D. Mehrotra, 2010, The Journal of infectious diseases.

Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.

Yongwu Shao, D. Porter, D. SenGupta, 2016, The lancet. HIV.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

The pharmacogenetics of antiretroviral therapy: a review of studies to date.

H. McLeod, W. Powderly, E. Quirk, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine

A. Clarke, M. Laouri, D. Wohl, 2018, The Patient - Patient-Centered Outcomes Research.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

J. Rockstroh, E. Daar, J. Molina, 2018, The lancet. HIV.

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.

P. Kwo, W. Kraft, M. Sulkowski, 2013, Antiviral research.

Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate in HIV-1-infected Adolescents Failing Antiretroviral Therapy: The Final Results of Study GS-US-104–0321

J. Pinto, E. Quirk, M. Z. de Aquino, 2015, The Pediatric infectious disease journal.

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

K. White, Ross Martin, E. Quirk, 2019, The Journal of antimicrobial chemotherapy.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

D. Podzamczer, H. Stellbrink, D. Ward, 2018, The lancet. HIV.

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

A. LaMarca, H. Stellbrink, F. Post, 2017, The lancet. HIV.

Virological Outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in Antiretroviral-Naive HIV-1-Infected Participants with Baseline HIV-1 RNA ≥1,000,000 Copies/ml: A Post Hoc Analysis of Phase III Clinical Trials

K. White, P. Sax, M. Das, 2018, Antiviral therapy.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

A. LaMarca, D. Podzamczer, A. Lazzarin, 2017, The lancet. HIV.

Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.

C. Kityo, V. Pokrovsky, A. Avihingsanon, 2019, Journal of acquired immune deficiency syndromes.

The pharmacogenetics of antiretroviral therapy: a review of studies to date.

H. McLeod, W. Powderly, E. Quirk, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

D. Podzamczer, H. Stellbrink, D. Ward, 2018, The lancet. HIV.